Athersys has entered a partnership with a nonprofit multiple sclerosis group to investigate its adult stem cell technology for the treatment of MS.
Fast Forward, a nonprofit subsidiary of the National Multiple Sclerosis Society, will commit up to $640,000 to fund animal studies of Athersys’ MultiStem in treating MS, a disease that attacks the central nervous system and can lead to paralysis, according to a statement from Cleveland-based Athersys.
The goal of the animal studies is to support the submission of an Investigational New Drug application to the U.S. Food and Drug Administration and then begin human trials in patients diagnosed with chronic progressive MS. If the MS project hits unspecified milestones related to development and commercialization, Athersys would remit some payments to Fast Forward....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1405
